CT
XENE icon

Cambridge Trust’s Xenon Pharmaceuticals XENE Stock Holding History

Cambridge Trust’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-300
Closed -$13.8K – 723
2023
Q4 		$13.8K Buy
+300
New +$10.6K ﹤0.01% 544

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cambridge Trust's XENE Position: Q1 2024 in Review

Cambridge Trust sold out of Xenon Pharmaceuticals (XENE) in Q1 2024, closing a stake of 300 shares — an estimated $13.8K sold.

Cambridge Trust first reported a position in XENE in Q4 2023 and held it in 1 quarter. The position peaked at $13.8K in Q4 2023. 220 funds tracked by Wall St. Rank hold XENE as of Q1 2024.

  • Cambridge Trust reported no remaining Xenon Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Cambridge Trust sold 300 Xenon Pharmaceuticals shares in Q1 2024, an estimated $13.8K.
  • Cambridge Trust first reported a position in Xenon Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Cambridge Trust's Xenon Pharmaceuticals position peaked at $13.8K in Q4 2023.
  • 220 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2024.

Based on Cambridge Trust's 13F filing for Q1 2024, filed 30 May 2024.